Fusarium rhinosinusitis post chimeric antigen receptor T-cell therapy
Supavit Chesdachai,
Natalia E. Castillo Almeida,
Isin Y. Comba,
Prasuna Muppa,
Matthew J. Thoendel
Affiliations
Supavit Chesdachai
Division of Infectious Diseases, Department of Medicine, Mayo Clinic, Rochester, MN, USA; Corresponding author at: Division of Infectious Diseases, Department of Medicine, 200 First Street SW, Rochester, MN, 55905, USA.
Natalia E. Castillo Almeida
Division of Infectious Diseases, Department of Medicine, Mayo Clinic, Rochester, MN, USA
Isin Y. Comba
Division of Infectious Diseases, Department of Medicine, Mayo Clinic, Rochester, MN, USA
Prasuna Muppa
Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA
Matthew J. Thoendel
Division of Infectious Diseases, Department of Medicine, Mayo Clinic, Rochester, MN, USA; Corresponding author at: Division of Infectious Diseases, Department of Medicine, 200 First Street SW, Rochester, MN, 55905, USA.
Chimeric antigen receptor T-cell (CAR-T) therapy is a novel treatment for various types of hematologic malignancy. We presented a case of refractory diffuse large B cell lymphoma patient who developed acute invasive fungal rhinosinusitis (AIFR) from Fusarium species after CAR-T therapy. Our photos illustrated the classic clinical, endoscopic, and histopathologic findings of AIFR.
